Skip to main content

Loading market data...

HUM

Humana Inc.

NYSE • United states

$431.00

+$3.62

(+0.85%)

Source: Yahoo Finance · Quote time Oct 21, 2026 13:46 GMT+0000

Management
Credibility
Score

Humana Inc. (HUM)

Unavailable

Quotes may be delayed

$51.75B

Market Cap

41,209

Volume

45.8

P/E Ratio

0.62%

Div Yield

Humana Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 500 W MAIN ST, LOUISVILLE, KY
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

13 Oct 2026

Humana Inc. reported Regulation FD disclosure

Humana Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.

9 Oct 2026

Humana Inc. reported Regulation FD disclosure

Humana Inc. filed an 8-K covering Regulation FD disclosure.

1 Sep 2026

Humana Inc. reported Regulation FD disclosure

Humana Inc. filed an 8-K covering Regulation FD disclosure.

29 Jul 2026

Humana Inc. filed Form 10-Q

Humana Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

29 Jul 2026

Humana Inc. reported A director or senior management change or compensation event

Humana Inc. filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$4.95B

Total assets (USD)$55.28B

Total liabilities (USD)$36.63B

Shareholders' equity (USD)$18.58B

Long-term debt (USD)$12.27B

Debt due within a year (USD)$1.72B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 31 Mar 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2026	$39.65B	$1.75B	$1.19B	$9.83	10-Q · 29 Apr 2026
Q4 2025	$32.52B	−$808.00M	−$796.00M	Unavailable	10-K · 19 Feb 2026
Q3 2025	$32.65B	$400.00M	$195.00M	$1.62	10-Q · 5 Nov 2025
Q2 2025	$32.39B	$1.10B	$545.00M	$4.51	10-Q · 30 Jul 2025
Q1 2025	$32.11B	$2.01B	$1.24B	$10.30	10-Q · 30 Apr 2025
Q4 2024	$29.21B	−$543.00M	−$693.00M	Unavailable	10-K · 20 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $458.86

6.5% upside potential

📈

Strong Buy

Unavailable

👍

Buy

15

⏸️

Hold

7

📉

Sell

1

23 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 13:48 UTC Targets range 280.00–596.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

1

Sep 2026

Nundy Shantanu

Chief Medical Officer

Grant or award

Unavailable per share

2,549 shares

1

Aug 2026

Smith Paul John

Director

Grant or award

Unavailable per share

544 shares

1

Aug 2026

Crawford Frederick John

Director

Grant or award

Unavailable per share

544 shares

1

May 2026

Mellet Celeste

Chief Financial Officer

Grant or award

Unavailable per share

15,387 shares

1

May 2026

Mehta Japan

Chief Information Officer

Grant or award

Unavailable per share

9,448 shares

1

May 2026

Dintenfass David

President, Enterprise Growth

Grant or award

Unavailable per share

11,273 shares

Top Shareholders

Vanguard Group Inc

14,261,860 shares

0.749% change

12/31/2025

Dodge & Cox

10,940,380 shares

-3.869% change

6/30/2026

Blackrock, Inc.

10,417,803 shares

2.145% change

6/30/2026

Vanguard Capital Management Llc

7,843,620 shares

0.062% change

6/30/2026

Vanguard Portfolio Management Llc

5,818,956 shares

0.181% change

6/30/2026

State Street Corp

5,457,072 shares

0.075% change

6/30/2026

Pzena Investment Management Llc

4,403,136 shares

-19.518% change

6/30/2026

Eagle Capital Management Llc

3,846,762 shares

29.648% change

6/30/2026

Sessa Capital Im, L.P.

3,727,740 shares

0% change

6/30/2026

Massachusetts Financial Services Co /Ma/

3,578,245 shares

-20.171% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 13:48 UTC· 18 hours ago

Research coverage and investment tools

Humana Inc. (HUM) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Medical Specialities). Its last price was US$431.00 on 21 Oct 2026. That is 91% of the way from its 52-week low of US$163.11 to its 52-week high of US$456.50. It paid US$2.66 a share in dividends over the last 12 months, a dividend yield of 0.62%. The latest ex-dividend date on file is 26 Jun 2026. Its market capitalisation was US$51.75 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2026	$39.65B	$1.75B	$1.19B	$9.83	—	4.4%	$1.13B	10-Q · 29 Apr 2026 (opens in a new tab)
Q4 2025	$32.52B	−$808.00M	−$796.00M	Unavailable	—	-2.5%	−$1.85B	10-K · 19 Feb 2026 (opens in a new tab)
Q3 2025	$32.65B	$400.00M	$195.00M	$1.62	—	1.2%	$836.00M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$32.39B	$1.10B	$545.00M	$4.51	—	3.4%	$1.16B	10-Q · 30 Jul 2025 (opens in a new tab)
Q1 2025	$32.11B	$2.01B	$1.24B	$10.30	—	6.3%	$236.00M	10-Q · 30 Apr 2025 (opens in a new tab)
Q4 2024	$29.21B	−$543.00M	−$693.00M	Unavailable	—	-1.9%	−$682.00M	10-K · 20 Feb 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/29/2026	$7.61	$6.22	+22.4%
Mar 2026	4/29/2026	$10.31	$9.97	+3.4%
Dec 2025	2/11/2026	−$3.96	−$4.01	+1.3%
Sep 2025	11/5/2025	$3.24	$2.91	+11.3%

Cash and equivalents: $4.95B
Total assets: $55.28B
Total liabilities: $36.63B
Shareholders' equity: $18.58B
Long-term debt: $12.27B
Debt due within a year: $1.72B

8-K · 13 Oct 2026

Humana Inc. reported Regulation FD disclosure (opens in a new tab)

Humana Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.
8-K · 9 Oct 2026

Humana Inc. reported Regulation FD disclosure (opens in a new tab)

Humana Inc. filed an 8-K covering Regulation FD disclosure.
8-K · 1 Sep 2026

Humana Inc. reported Regulation FD disclosure (opens in a new tab)

Humana Inc. filed an 8-K covering Regulation FD disclosure.
10-Q · 29 Jul 2026

Humana Inc. filed Form 10-Q (opens in a new tab)

Humana Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 29 Jul 2026 · Management change

Humana Inc. reported A director or senior management change or compensation event (opens in a new tab)

Humana Inc. filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Nundy Shantanu Chief Medical Officer	1 Sep 2026	Grant or award (A)	+2,549	—	Form 4 (opens in a new tab)
Smith Paul John Director	1 Aug 2026	Grant or award (A)	+544	—	Form 4 (opens in a new tab)
Crawford Frederick John Director	1 Aug 2026	Grant or award (A)	+544	—	Form 4 (opens in a new tab)
Mellet Celeste Chief Financial Officer	1 May 2026	Grant or award (A)	−15,387	—	Form 4 (opens in a new tab)
Mehta Japan Chief Information Officer	1 May 2026	Grant or award (A)	+9,448	—	Form 4 (opens in a new tab)
Dintenfass David President, Enterprise Growth	1 May 2026	Grant or award (A)	+11,273	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	14,261,860	0.749%
Dodge & Cox	6/30/2026	10,940,380	-3.869%
Blackrock, Inc.	6/30/2026	10,417,803	2.145%
Vanguard Capital Management Llc	6/30/2026	7,843,620	0.062%
Vanguard Portfolio Management Llc	6/30/2026	5,818,956	0.181%
State Street Corp	6/30/2026	5,457,072	0.075%
Pzena Investment Management Llc	6/30/2026	4,403,136	-19.518%
Eagle Capital Management Llc	6/30/2026	3,846,762	29.648%
Sessa Capital Im, L.P.	6/30/2026	3,727,740	0%
Massachusetts Financial Services Co /Ma/	6/30/2026	3,578,245	-20.171%

Previous close: 427.38 USD
Day range: 430.75 – 433.44 USD
52-week range: 163.11 – 456.50 USD
Volume: 41,209
Market cap: $51.75B
Average volume: 707,548
P/E ratio: 45.8
EPS (FY 2025, diluted): 9.84 USD
Dividends (last 12 months): 2.66 USD
Dividend yield: 0.62%
Ex-dividend date: 26 Jun 2026
Shares outstanding: 120.08M
Beta (5Y monthly): 0.65

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 13:46 UTC· 18 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:18 UTC· 1 hour ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:18 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for HUM yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.